What are the causes, symptoms, and treatment options for intestinal inflammation in women?

Intestinal Inflammation in Women: Causes, Symptoms, and Treatment

Intestinal inflammation in women is primarily caused by inflammatory bowel disease (IBD)—ulcerative colitis and Crohn's disease—which requires aggressive disease control to prevent serious complications including preterm delivery, low birth weight, and increased maternal morbidity, particularly during reproductive years.

Causes

The two main forms of IBD are ulcerative colitis (UC) and Crohn's disease (CD), which represent chronic inflammatory conditions affecting the gastrointestinal tract 1. These diseases:

• Occur in genetically susceptible individuals who mount inappropriate immune responses to their intestinal microbiota, leading to chronic inflammation 2
• Affect women differently than men, with distinct clinical presentations and disease severity patterns 3
• Typically onset in early adulthood, making them particularly relevant during reproductive years 4
• Are more prevalent in Western nations including Canada, the United States, and Europe 1

Risk Factors Specific to Women

• Smoking significantly worsens Crohn's disease and is the most important modifiable risk factor 1
• Hormonal fluctuations during menstrual cycles can worsen IBD symptoms without correlating to actual disease activity 5
• Endometriosis occurs more frequently in women with IBD compared to those without 5

Symptoms

General IBD Symptoms

Women with IBD experience:

• Abdominal pain and cramping
• Diarrhea (often bloody in ulcerative colitis)
• Rectal bleeding
• Weight loss and malnutrition
• Fatigue
• Fever during active disease flares

Women-Specific Considerations

• Women report worse psychological well-being and less resilience than men with IBD 5
• Higher disease activity has been documented in female patients compared to male patients 6
• Sexual dysfunction is common but rarely discussed with healthcare providers 5
• Depression significantly impairs quality of sexual life 5
• Symptoms worsen during menstruation without corresponding increases in objective disease activity 5

Perianal Disease (Crohn's Disease)

• Perianal fistulae and abscesses are particularly important in women as they affect delivery decisions 1
• Active perianal disease requires cesarean delivery to prevent further injury 1

Treatment

General Treatment Principles

The primary goal is achieving and maintaining clinical remission, as active disease—especially at conception—significantly increases risks of adverse pregnancy outcomes and infant mortality 1.

First-Line Maintenance Therapy

5-Aminosalicylates (5-ASA/Mesalamine):

• Continue throughout pregnancy and breastfeeding for women on maintenance therapy 1
• Doses ≥2 g/day are required for effectiveness in Crohn's disease 1
• Combination oral and rectal therapy should be optimized for mild-to-moderate ulcerative colitis flares 1
• If taking sulfasalazine, supplement with folic acid 5 mg daily (not just 400 μg) starting 3 months before conception to prevent neural tube defects 1

Second-Line Immunomodulators

Thiopurines (Azathioprine/Mercaptopurine):

• Continue throughout pregnancy for women on maintenance therapy 1
• Dosing: Azathioprine 1.5-2.5 mg/kg/day or Mercaptopurine 0.75-1.5 mg/kg/day 1
• Monitor complete blood count within 4 weeks of starting, then every 6-12 weeks to detect neutropenia 1
• Effective for maintaining remission and treating steroid-dependent disease 1

Biologic Therapy (Anti-TNF Agents)

Continue anti-TNF therapy throughout pregnancy for women on maintenance treatment 1. This is critical because:

• Discontinuing therapy increases relapse risk, which poses greater danger to mother and fetus than medication exposure 1
• In highly select low-risk patients only, the last dose may be given at 22-24 weeks gestation to minimize fetal exposure 1
• Infliximab dosing: 5-10 mg/kg every 8 weeks for maintenance after initial induction 1

Treatment of Active Disease Flares

For mild-to-moderate flares on optimized 5-ASA or thiopurine therapy:

• Initiate systemic corticosteroids or anti-TNF therapy to induce remission 1

For corticosteroid-resistant flares:

• Start anti-TNF therapy immediately 1

For perianal sepsis in Crohn's disease:

• Metronidazole 400 mg three times daily and/or ciprofloxacin 500 mg twice daily as first-line treatment 1

Medications to AVOID

Methotrexate:

• MUST be stopped at least 3 months before attempting conception due to teratogenicity risk 1
• If pregnancy occurs while taking methotrexate, immediately discontinue and refer for obstetric counseling 1
• Avoid during breastfeeding 1

JAK inhibitors and sphingosine-1-P modulators:

• Stop at least 3 months before conception 1

Corticosteroids:

• Not effective for maintenance therapy and should not be used long-term 1
• Budesonide is ineffective for maintaining remission 1

Adjunctive Treatments

Iron deficiency anemia (very common in active IBD):

• Do not use oral iron tablets during active disease as systemic inflammation inhibits absorption 1
• Limit to 100 mg elemental iron daily in inactive disease, or use one tablet every other day if not tolerated 1
• Consider parenteral iron for active disease or intolerance 1
• Ferritin up to 100 μg/L may still reflect iron deficiency in the presence of inflammation; check transferrin saturation 1

Vitamin supplementation:

• Daily vitamin D for all women with IBD 1
• Folic acid 400 μg/day for everyone; 5 mg/day for those on sulfasalazine or with small bowel disease/resections 1

Smoking cessation:

• All smokers must be strongly advised to stop with counseling, nicotine patches, or substitutes offered 1

Surgical Considerations

• Endoscopy or urgent surgery should not be delayed during pregnancy if clinically indicated 1
• Flexible sigmoidoscopy or colonoscopy should be performed if results will affect management 1
• Limit imaging to ultrasound and MRI without gadolinium during pregnancy 1

Thromboembolism Prophylaxis

Women with IBD have increased VTE risk:

• Anticoagulant thromboprophylaxis during hospitalization for IBD flares 1
• VTE prophylaxis after cesarean delivery 1
• Outpatients with active IBD should receive VTE prophylaxis during third trimester unless contraindicated 1

Critical Management Pitfalls

Common treatment errors in women:

• Women receive significantly less immunosuppressive medication than men despite having higher disease activity 6
• This treatment disparity exists even in women of childbearing potential versus menopausal women, suggesting inappropriate withholding of effective therapy 6
• Active disease at conception carries far greater risk than medication exposure; maintaining remission is paramount 1

Preconception counseling is essential and should include:

• Objective disease assessment before conception 1
• Aim for 3 months of remission before attempting pregnancy 1
• Medication optimization for efficacy and safety 1
• Individualized management plans for pregnancy 1

Specialist care requirements:

• All pregnant women with IBD should be managed by a gastroenterologist throughout pregnancy 1
• Consultation with high-risk obstetrics for active or complicated disease 1
• Transfer to tertiary centers if hospitalization required 1